BML Capital Management LLC Increases Stock Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Key Points

• BML Capital Management LLC increased its position in Oramed Pharmaceuticals Inc. by 14.3% during the first quarter, adding 376,841 shares to hold a total of 3,020,748 shares.
• The company reported a quarterly loss of ($0.19) EPS, missing the consensus estimate by ($0.16) with a revenue of $2 million.
• Wall Street analysts have recently downgraded Oramed Pharmaceuticals from a "hold" to a "sell" rating, indicating potential concerns about the stock’s future performance.

BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 14.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,020,748 shares of the biotechnology company's stock after purchasing an additional 376,841 shares during the quarter. Oramed Pharmaceuticals accounts for about 5.0% of BML Capital Management LLC's holdings, making the stock its 8th biggest holding. BML Capital Management LLC owned approximately 7.39% of Oramed Pharmaceuticals worth $6,464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of ORMP. Boothbay Fund Management LLC lifted its holdings in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock worth $2,045,000 after acquiring an additional 16,857 shares during the last quarter. Peapod Lane Capital LLC lifted its holdings in shares of Oramed Pharmaceuticals by 11.0% in the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock worth $540,000 after acquiring an additional 24,985 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Oramed Pharmaceuticals by 143.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after acquiring an additional 70,190 shares during the last quarter. 12.73% of the stock is currently owned by institutional investors.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP traded down $0.03 during mid-day trading on Tuesday, hitting $2.19. The stock had a trading volume of 62,011 shares, compared to its average volume of 148,552. Oramed Pharmaceuticals Inc. has a 1 year low of $1.82 and a 1 year high of $3.09. The business has a 50 day moving average price of $2.17 and a two-hundred day moving average price of $2.23. The firm has a market cap of $89.26 million, a P/E ratio of -4.97 and a beta of 1.59.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.16). The company had revenue of $2.00 million for the quarter. Equities research analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.